GRAFIL
Product Code: 01
Pack Size: 1 Vial
- Price: $23.51 ৳0 ,
Grafil pre-filled syringe injection: Each pre-filled syringe contains 0.5 ml sterile solution of Filgrastim BP 300 mcg (30 MU).
Filgrastim is Indicatod forCancer patients receiving myelosuppressive chemotherapy : The decrease of the incidence of infection, as manifested by febrile neutropenia, in patients with non myeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever Cancer patients undergoing Acute Myeloid Leukemia: The reduction of the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). Cancer Patients Receiving Bone Marrow Transplantation (BMT): The reduction of the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablatlve chemotherapy followed by bone marrow transplantation. Patients with severe chronic neutropenia : The reduction of the incidence and duration of sequelae of neutropenia (e.g., fever, infection or opharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia or idiopathic neutropenia. Patients acutely exposed to myelosuppressive doses of radiation: The increase of the survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic syndrome of acute radiation syndrome). Patients with HIV infection: The prevention and treatment of persistent neutropenia (ANC <_ 1.0 x 109/I) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections, when other options to manage neutropenia are inappropriate.
Major Ingredients
Grafil pre-filled syringe injection: Each pre-filled syringe contains 0.5 ml sterile solution of Filgrastim BP 300 mcg (30 MU).
Major Functionality
Filgrastim is Indicatod forCancer patients receiving myelosuppressive chemotherapy : The decrease of the incidence of infection, as manifested by febrile neutropenia, in patients with non myeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever Cancer patients undergoing Acute Myeloid Leukemia: The reduction of the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). Cancer Patients Receiving Bone Marrow Transplantation (BMT): The reduction of the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablatlve chemotherapy followed by bone marrow transplantation. Patients with severe chronic neutropenia : The reduction of the incidence and duration of sequelae of neutropenia (e.g., fever, infection or opharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia or idiopathic neutropenia. Patients acutely exposed to myelosuppressive doses of radiation: The increase of the survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic syndrome of acute radiation syndrome). Patients with HIV infection: The prevention and treatment of persistent neutropenia (ANC <_ 1.0 x 109/I) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections, when other options to manage neutropenia are inappropriate.
Manufacture Information
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.
